AbbVie Inc.: 10-K Risk Factor Changes

2025 vs 2024  ·  SEC EDGAR  ·  2026-07-05
Other years: 2026 vs 2025
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

0
New Risks
1
Removed
4
Modified
26
Unchanged
🟡 Modified AbbVie depends on information technology and a failure of, or significant disruption to, those systems, or a failure to adequately adopt emerging technologies such as artificial intelligence, could have a material adverse effect on AbbVie's business. 🔒
🔴 No Match in Current Filing Public health outbreaks, epidemics or pandemics, such as the coronavirus (COVID-19), have had, and could in the future have, an adverse impact on AbbVie’s operations and financial condition. 🔒
🟡 Modified AbbVie's research and development efforts may not succeed in developing products and technologies that can be successfully commercialized, which may cause its revenues and profitability to decline. 🔒
🟡 Modified The manufacture of many of AbbVie's products is a highly exacting and complex process requiring critical environmental controls, and if AbbVie or one of its suppliers encounters problems manufacturing AbbVie's products, AbbVie's business could suffer. 🔒
🟡 Modified New products and technological advances by AbbVie's competitors may negatively affect AbbVie's results of operations. 🔒
5 changes in this historical filing

Historical year-over-year comparisons (2025 vs 2024 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →